(Rac)-ZLc-002

• CAT Number: I041429
• Molecular Formula: C10H17NO5
• Molecular Weight: 231.25
• Purity: ≥95%
• Synonyms: methyl 2-[(3-methoxy-3-oxopropanoyl)amino]-3-methylbutanoate
• InChI: InChI=1S/C10H17NO5/c1-6(2)9(10(14)16-4)11-7(12)5-8(13)15-3/h6,9H,5H2,1-4H3,(H,11,12)
• InChIKey: BWPKYDAJBOUZDX-UHFFFAOYSA-N
• SMILES: CC(C)C(C(=O)OC)NC(=O)CC(=O)OC

(Rac)-ZLc-002, an inhibitor of nNOS interaction with nitric oxide synthase 1 adaptor protein (NOS1AP), suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with Paclitaxel (HY-B0015) to reduce tumor cell viability[1][2].
(Rac)-ZLc-002 (10 μM) reduces co-immunoprecipitation of NOS1AP with nNOS immunoprecipitated from primary cultured cortical neurons. (Rac)-ZLc-002 fails to disrupt nNOS–NOS1AP protein–protein interactions in the AlphaScreen in vitro binding assay. It shows no activity in a cell-free assay[1].
(Rac)-ZLc-002 (10 μM) reduces co-immunoprecipitation of full-length NOS1AP but not of PSD95-PDZ2 from HEK293T cells co-expressing full-length nNOS[1].
(Rac)-ZLc-002 (0-50 μM; 72 h) synergizes with Paclitaxel (HY-B0015) to reduce tumor cell viability[1].
(Rac)-ZLc-002 (10 mg/kg; i.p.; once or daily for 8 days) attenuates mechanical and cold allodynia evoked by Paclitaxel (HY-B0015), suppresses Paclitaxel-induced neuropathic pain in a mouse model[1].
(Rac)-ZLc-002 (4 and 10 mg/kg; i.p.; once) reduces formalin-evoked nociceptive behavior and Fos-like immunoreactivity in the spinal dorsal horn in rats[1].
(Rac)-ZLc-002 (40 mg/kg/day; i.v.; 7 days) attenuates chronic mild stress (CMS)‐induced anxiogenic behavior in ICR mice[2].
(Rac)-ZLc-002 (10 μM; 1 μl; 30 min after Corticosterone, HY-B1618) delivering into the hippocampus for 7 days reverses the behavioural effects of glucocorticoids in mice[2].

Reference

[1]. Lee WH, Carey LM, Li LL, et al. ZLc002, a putative small-molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability. Mol Pain. 2018;14:1744806918801224.
 [Content Brief]

[2]. Zhu LJ, Shi HJ, Chang L, et al. nNOS-CAPON blockers produce anxiolytic effects by promoting synaptogenesis in chronic stress-induced animal models of anxiety. Br J Pharmacol. 2020;177(16):3674-3690.
 [Content Brief]